scPharma

scPharma is a commercial-stage pharmaceutical company focused on developing and commercializing products that enable the subcutaneous administration of therapies traditionally delivered intravenously. The company's lead product, Furoscix, is an FDA-approved subcutaneous formulation of furosemide delivered via a wearable on-body infusor for the treatment of congestion in patients with heart failure. By shifting care from the hospital to the home, scPharma aims to reduce healthcare costs and improve patient outcomes. Their pipeline includes additional subcutaneous formulations of antibiotics for outpatient treatment of infections. The company leverages its proprietary delivery technology to transform the patient experience and optimize healthcare resource utilization.